
Allergic Reactions Do Not Blunt Sublingual Epinephrine: Jay Lieberman, MD
Jay Lieberman, MD, discusses integrated dibutepinephrine sublingual film data in patients with and without allergic reaction symptoms at ACAAI 2026.
Dibutepinephrine (Anaphylm) sublingual film maintained its pharmacokinetic and pharmacodynamic profile during localized
Lieberman presented the late-breaking oral abstract at the
"It is hard to do these studies in true anaphylaxis, right? Put someone through anaphylaxis and then randomize them to a treatment. It is unethical in some ways, but to see data in an acute allergic reaction that's attempting to mimic anaphylaxis is very reassuring," Lieberman said.
Lieberman said epinephrine concentrations rose slightly faster and higher during the localized reaction than without symptoms, and the curves resembled those from the earlier healthy-adult studies. He noted intranasal epinephrine products were evaluated with a comparable nasal allergen challenge model.
If approved, the film would join autoinjectors and intranasal epinephrine as options, Lieberman said, adding he prescribes whichever form a patient will carry and use and the film’s small size may help with carrying. After the FDA declined to approve the film earlier this year, Lieberman said the agency’s response focused on patient experience issues.⁴
The FDA
Lieberman’s disclosures include Aquestive Therapeutics.
References
Lieberman JA, et al. Dibutepinephrine pharmacokinetics/pharmacodynamics in patients with and without symptoms of a type I allergic reaction. Presented at: ACAAI 2026 Annual Scientific Meeting; November 12-16, 2026; Phoenix, AZ.
Nowak-Wegrzyn A, Fleischer DM, Lieberman JA, et al. Pharmacokinetics and pharmacodynamics of AQST-109 sublingual film in oral allergy syndrome: a phase 2 study. Ann Allergy Asthma Immunol. Published online June 28, 2026. doi:10.1016/j.anai.2026.06.012
Kraus CN, Wargacki S, Golden D, et al. Integrated phase I pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection. Ann Allergy Asthma Immunol. 2025.
Brooks A. FDA issues CRL to dibutepinephrine (Anaphylm) sublingual film for type 1 allergic reactions. HCPLive. February 2, 2026. Accessed November 15, 2026.
https://www.hcplive.com/view/fda-issues-crl-to-dibutepinephrine-anaphylm-sublingual-film-for-type-1-allergic-reactions Aquestive Therapeutics announces FDA acceptance of Anaphylm NDA resubmission and PDUFA goal date of March 16, 2027. Aquestive Therapeutics. October 15, 2026. Accessed November 15, 2026.
Related to this article








